Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Canada approves GSK's Arexvy for RSV prevention in adults aged 50 to 59

November 11, 2024
In a major breakthrough, Health Canada has approved GSK's Arexvy, a vaccine for preventing respiratory syncytial virus (RSV) infections, in adults aged 50 to 59. RSV is a common respiratory virus that can cause severe illness, particularly in older adults. This approval marks a significant milestone for GSK, as it is the first vaccine specifically developed for RSV prevention in this age group. Arexvy has shown promising results in clinical trials, demonstrating a high efficacy rate and an excellent safety profile. This positive development is expected to boost GSK's revenue and reaffirm its commitment to improving public health. Investors are advised to seek professional guidance from Stocks Prognosis for accurate predictions on GSK's stock movement.

Find out how the GSK PLC rate is expected to change

Get Forecast for GSK

Investor opinions & comments:

I'm excited to see how this development will impact GSK's revenue. With such a high demand for RSV prevention in older adults, the vaccine could be a financial success
— from PenelopeWest at 11-14-2024 07:24
This breakthrough could have far-reaching implications for global health. It sets a precedent for the development of vaccines targeting specific age groups and diseases
— from OwenSullivan at 11-13-2024 19:50
I'm confident that GSK's commitment to improving public health will continue to drive their research and development efforts. Exciting times ahead!
— from RiskyRachel at 11-13-2024 17:55
I'm glad to see GSK's commitment to improving public health. This vaccine could potentially save many lives and reduce the burden on healthcare systems
— from VictoriaKelley at 11-13-2024 06:30
Arexvy's approval is not only a win for GSK but also for all the people who will benefit from this vaccine. It's a step towards better healthcare for older adults
— from MeganThompson at 11-12-2024 22:47
Arexvy's high efficacy rate in clinical trials is promising. It gives hope that the vaccine will effectively protect adults aged 50 to 59 from severe RSV infections
— from CapitalChris at 11-12-2024 19:13
I'm impressed by the progress made in medical science. Arexvy's approval is a testament to the dedication and expertise of researchers working towards protecting public health
— from VictoriaKelley at 11-12-2024 16:49
I wonder how long-lasting the protection from Arexvy will be. Will adults need to get vaccinated every year, or will a single dose provide long-term immunity?
— from InvestorIshmael at 11-12-2024 15:36
It's great that Arexvy has shown a high efficacy rate in clinical trials, but I would like to see more data on its safety profile in a larger population
— from AdamWells at 11-12-2024 14:34
This is a groundbreaking achievement for GSK! It's impressive that they have developed the first vaccine specifically for RSV prevention in adults aged 50 to 59
— from CalebBishop at 11-12-2024 11:07
I'm curious about the potential side effects of Arexvy. Has there been any mention of adverse reactions in the clinical trials?
— from SarahAllen at 11-12-2024 02:48
This is great news! RSV can be a serious illness in older adults, so having a vaccine specifically for this age group is a major step forward in preventing infections
— from RachelLee at 11-12-2024 02:05
I appreciate GSK's efforts in developing a vaccine specifically for older adults. RSV can be particularly dangerous in this age group, so prevention is key
— from TraderTobias at 11-12-2024 01:22
I hope this vaccine will be accessible and affordable for adults aged 50 to 59. It's important that everyone who needs it can have access to it
— from DanielTaylor at 11-11-2024 22:25
I'm hopeful that this vaccine will reduce the number of severe RSV infections in older adults and improve their quality of life. Great news for public health!
— from FinanceDave at 11-11-2024 10:34
Arexvy's approval by Health Canada is a significant milestone for GSK. It shows their dedication to addressing unmet medical needs and improving public health
— from InvestorIvy at 11-11-2024 10:25
This news is a win for public health. The availability of a vaccine for preventing RSV infections in adults aged 50 to 59 will contribute to a healthier population
— from MarketMikayla at 11-11-2024 08:51
Health Canada's approval of Arexvy is a testament to the vaccine's safety and effectiveness. It's reassuring to know that it has undergone rigorous evaluation before being approved
— from BrittanyClark at 11-11-2024 08:15
If you want to leave a comment, then you need Login or Register





Other news for GSK

GSKJune 2, 2025QuantWave Delivers 7.39% Profit with Successful GSK PLC Stock Price Target Forecast  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, signaled a long position for GSK PLC at a price of 38.79 $. Today, on June 2, 2025, the stock reached the predicted target price of 41....

GSKJune 2, 2025QuantWave Hits Price Target Forecast for GSK PLC, Yielding 8.78% Profit  ~1 min.

QuantWave, the automated forecasting platform, successfully achieved its price target forecast for GSK PLC, resulting in a profit of 8.78%....

GSKJune 2, 2025QuantWave Achieves GSK PLC Price Target Forecast with 6.93% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, has successfully hit the price target forecast for GSK PLC, resulting in a profitable trade with a 6.93% gain....

GSKJune 2, 2025QuantWave Achieves 8.39% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, an automated forecasting platform, has successfully hit a price target forecast for the stock of GSK PLC, resulting in a profit of 8.39%....

GSKJune 2, 2025QuantWave Achieves 11.28% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a long position for GSK PLC on April 1, 2025, when the stock was trading at $37.44....



Related news

AZNJanuary 1, 2025Stocks Prognosis: Is AstraZeneca PLC AZN Set to Become a U.K. Dividend Champion by 2024?  ~2 min.

AstraZeneca PLC, a leading global pharmaceutical company, is garnering attention from investors as it seeks to establish itself as a U.K. Dividend Champion by 2024....

REGNJanuary 1, 2025Regeneron Pharmaceuticals Inc. Shows Impressive Growth and Promising Future  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been making significant strides in the healthcare sector, and investors have reaped the benefits....

IBMJanuary 1, 2025IBM's Breakthrough in Nanotechnology Drives Investor Interest  ~2 min.

Investors are showing a keen interest in International Business Machines Corporation (IBM) after the company announced a major breakthrough in nanotechnology....

AZNDecember 6, 2024Why AstraZeneca PLC AZN is Poised for Success in the Pharmaceutical Industry  ~2 min.

AstraZeneca PLC (AZN) has emerged as one of the most profitable pharmaceutical stocks in the market....

AZNNovember 10, 2024AstraZeneca PLC AZN: A Company on the Rise, Stocks Prognosis Recommends Buying  ~2 min.

AstraZeneca PLC (AZN), a global biopharmaceutical company, is steadily climbing the success ladder, and Stocks Prognosis recommends taking advantage of this upward trend by investing in their stocks....